U.S. President Donald Trump announced agreements with pharmaceutical companies Novo Nordisk and Eli Lilly to reduce prices for their obesity drugs Wegovy and Zepbound, respectively, including $50 monthly copays for Medicare patients starting mid-2026 and expanded coverage for those with severe obesity.
Trump Announces Cost Cuts to Weight Loss Drugs